Patents Assigned to University of Otago
-
Patent number: 11439674Abstract: The present invention provides methods of treating or preventing at least one of postnatal depression (PND) and postnatal anxiety (PNA), and risks and sequelae thereof, by administering Lactobacillus rhamnosus HN001 or derivatives thereof, in addition to uses, compositions, and medicaments comprising Lactobacillus rhamnosus HN001 or derivatives thereof to treat or prevent at least one of PND and PNA, and risks and sequelae thereof.Type: GrantFiled: June 2, 2017Date of Patent: September 13, 2022Assignee: University of OtagoInventors: Rebecca Slykerman, Edwin Arthur Mitchell, Thorsten Villiers Stanley
-
Patent number: 11395839Abstract: The present invention provides methods of treating or preventing gestational diabetes by administering Lactobacillus rhamnosus HN001 or derivatives thereof, in addition to uses, compositions, and medicaments comprising Lactobacillus rhamnosus HN001 or derivatives thereof to treat or prevent gestational diabetes mellitus.Type: GrantFiled: June 2, 2017Date of Patent: July 26, 2022Assignee: University of OtagoInventor: Kristin Lee Wickens
-
Patent number: 11260126Abstract: The present invention provides acoustically activated liposome compositions for use as drug delivery vehicles, and to methods for drug release and drug delivery for therapeutic applications.Type: GrantFiled: August 19, 2016Date of Patent: March 1, 2022Assignee: University of OtagoInventors: John Noble James Reynolds, Eng Wui Tan, Brian Ian Hyland, Guy Nicholas Louis Jameson, Maung Mo Aung Myint, Sean Marshall Mackay, Jeffery Russell Wickens
-
Patent number: 9045505Abstract: The invention relates to novel NO donors which are targeted to the mitochondria. The NO donor compounds of the invention allow NO to be selectively provided to the mitochondria.Type: GrantFiled: March 26, 2010Date of Patent: June 2, 2015Assignees: University of Otago, Medical Research CouncilInventors: Robin Andrew James Smith, Michael Patrick Murphy
-
Publication number: 20130064768Abstract: The present invention provides an imaging probe which comprises a lipophilic cation, a hydrophobic moiety and a PET nucleus. The present invention also provides a precursor molecule for the production of such an imaging probe and methods for using the probe for analysing mitochondrial membrane potential in a subject.Type: ApplicationFiled: March 24, 2011Publication date: March 14, 2013Applicants: Medical Research Council, University of Otago, Cambridge Enterprise LimitedInventors: David K. Menon, Michael P. Murphy, Franklin I. Aigbirhio, Robin A. Smith
-
Patent number: 7989602Abstract: The present invention is directed to synthetic molecules having biological activity similar to PIM (acyl glycerol phosphatidylinositol manno-oligosaccharide) activity, for use in the treatment and prevention of inflammatory or immune cell mediated diseases or disorders.Type: GrantFiled: November 18, 2004Date of Patent: August 2, 2011Assignees: The Malaghan Institute of Medical Research, University of Otago, Agresearch LimitedInventors: Gurmit Singh-Gill, David Samuel Larsen, Jeremy David Jones, Wayne Bruce Severn, Jacquie Lucille Harper, Gavin Painter
-
Publication number: 20090233873Abstract: The invention relates to novel NO donors which are targeted to the mitochondria. The NO donor compounds of the invention allow NO to be selectively provided to the mitochondria.Type: ApplicationFiled: March 27, 2009Publication date: September 17, 2009Applicants: University of Otago, Medical Research CouncilInventors: Robin Andrew James Smith, Michael Patrick Murphy
-
Publication number: 20080020070Abstract: The use of a citrus fruit skin extract for promoting angiogenesis, or treating a disease or disorder where it is desirable to promote angiogenesis. Such diseases include coronary heart disease, stroke, or ulcers. A composition comprising an extract of citrus fruit skin suitable for use in promoting angiogenesis, or treating a disease or disorder where it is desirable to promote angiogenesis. A process for preparing a citrus fruit skin extract. The citrus fruit may be grapefruit, orange, lemon, lime, mandarin, tangelo, tangerine or uglis, preferably grapefruit (Citrus paradisii).Type: ApplicationFiled: April 29, 2005Publication date: January 24, 2008Applicants: Industrial Research Limited, University of Otago, Otago Innovation LimitedInventors: Paul Davis, Lai Foo
-
Publication number: 20070292966Abstract: A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.Type: ApplicationFiled: June 17, 2004Publication date: December 20, 2007Applicant: University of OtagoInventors: Timothy Prickett, Eric Espiner, Arthur Richards, Timothy Yandle, Michael Nicholls
-
Patent number: 7109189Abstract: The invention provides mitochondrially targeted antioxidant compounds comprising a lipophilic cation moiety covalently coupled to a glutathione peroxidase mimetic. These compounds can be used to treat patients who would benefit from the reduction of oxidative stress.Type: GrantFiled: February 11, 2005Date of Patent: September 19, 2006Assignees: University of Otago, Medical Research CouncilInventors: Michael P. Murphy, Robin A. J. Smith
-
Patent number: 6984636Abstract: The invention provides mitochondrially targeted antioxidant compounds comprising a lipophilic cation moiety covalently coupled to an antioxidant moiety which is either a superoxide dismutase (SOD) mimetic or a glutathione peroxidase mimetic. These compounds can be used to treat patients who would benefit from the reduction of oxidative stress.Type: GrantFiled: August 12, 2002Date of Patent: January 10, 2006Assignees: Medical Research Council, University of OtagoInventors: Michael P. Murphy, Robin A. J. Smith
-
Publication number: 20050227957Abstract: The invention provides mitochondrially targeted antioxidant compounds comprising a lipophilic cation moiety covalently coupled to a glutathione peroxidase mimetic. These compounds can be used to treat patients who would benefit from the reduction of oxidative stress.Type: ApplicationFiled: February 11, 2005Publication date: October 13, 2005Applicants: Medical Research Council, University of OtagoInventors: Michael Murphy, Robin Smith
-
Patent number: 6773912Abstract: This invention provides an antibacterial protein, Salivaricin B. Salivaricin B is bacteriocidal with respect to, inter alia, S. pyogenes and therefore has numerous therapeutic applications. These applications include, but are not limited to, forming part of therapeutic formulations for use in treating or preventing streptococcal infections of the throat.Type: GrantFiled: December 21, 2001Date of Patent: August 10, 2004Assignees: University of Otago, Blis Technologies LimitedInventors: John Robert Tagg, Karen Patricia Dierksen, Mathew Upton
-
Publication number: 20040106579Abstract: The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph3)+XR.Z- where X is a linking group, Z is an anion and R is an antioxidant moiety. Also provided are pharmaceutical compositions containing the mitochondrially targeted antioxidant compounds, and methods of therapy or prophylaxis of patients who would benefit from reduced oxidative stress, which comprise the step of administering the compounds of the invention.Type: ApplicationFiled: November 28, 2003Publication date: June 3, 2004Applicant: University of OtagoInventors: Michael P. Murphy, Robin A.J. Smith
-
Publication number: 20040029851Abstract: The invention provides mitochondrially targeted antioxidant compounds comprising a lipophilic cation moiety covalently coupled to an antioxidant moiety which is either a superoxide dismutase (SOD) mimetic or a glutathione peroxidase mimetic. These compounds can be used to treat patients who would benefit from the reduction of oxidative stress.Type: ApplicationFiled: August 12, 2002Publication date: February 12, 2004Applicants: Medical Research Council, University of OtagoInventors: Michael P. Murphy, Robin A.J. Smith
-
Publication number: 20030069208Abstract: The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph3)+XR·Z− where X is a linking group, Z is an anion and R is an antioxidant moiety. Also provided are pharmaceutical compositions containing the mitochondrially targeted antioxidant compounds, and methods of therapy or prophylaxis of patients who would benefit from reduced oxidative stress, which comprise the step of administering the compounds of the invention.Type: ApplicationFiled: October 18, 2002Publication date: April 10, 2003Applicant: University of OtagoInventors: Michael P. Murphy, Robin A.J. Smith
-
Patent number: 6541008Abstract: The invention is based on the discovery that a viral VEGF-like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the VEGF receptor-2 to form bioactive complexes which mediate useful cellular responses and/or antagonize undesired biological activities. Disclosed are methods which stimulate or inhibit these biological activities, methods for therapeutic applications and antagonists of ORFV2-VEGF and/or NZ10.Type: GrantFiled: November 2, 1999Date of Patent: April 1, 2003Assignees: University of Otago, Ludwig Institute for Cancer ResearchInventors: Lyn M. Wise, Andrew A. Mercer, Loreen J. Savory, Stephen B. Fleming, Steven A. Stacker
-
Publication number: 20030013076Abstract: The invention is directed to parapoxvirus vectors. Specifically provided are orf virus vectors containing exogenous DNA. The exogenous DNA may encode a heterologous peptide or polypeptide of which expression is desired, or may encode an antigen capable of inducing an immune response. The capacity to express antigens make these vectors suitable for use in vaccines.Type: ApplicationFiled: March 2, 2001Publication date: January 16, 2003Applicant: University of OtagoInventors: Anthony J. Robinson, David J. Lyttle
-
Patent number: 6403130Abstract: A polymer is provided which comprises acid casein or a non-toxic soluble salt thereof and high-methoxyl pectin cross-linked into a three-dimensional network. A process for preparing the polymer and edible films and food products comprising the polymer are also provided.Type: GrantFiled: September 1, 1999Date of Patent: June 11, 2002Assignees: Kiwitech Limited, University of OtagoInventor: Richard Beyer
-
Patent number: D495138Type: GrantFiled: August 28, 2003Date of Patent: August 31, 2004Assignee: University of OtagoInventor: Gavin Paul O'Brien